nach oben

European Archives of Oto-Rhino-Laryngology

Erschienen in:

14.05.2015 | Review Article

The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature

verfasst von: Giovanni Cammaroto, Natale Quartuccio, Alessandro Sindoni, Francesca Di Mauro, Federico Caobelli, Young AIMN Working Group

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

The management of head and neck tumor (HNSCC) has been changing over the years, especially due to the aid of imaging techniques that help physicians to attain a correct diagnosis. These techniques represent a valuable tool to help tailor treatment and during follow-up of patients affected by malignancies. The aim of this review is to summarize the results of the most recent and relevant studies about the use of PET imaging in HNSCCs. This review is divided into six chapters: (1) The role of PET/CT in the pre-treatment phase; (2) PET/CT and radiotherapy planning; (3) PET/CT in the post-treatment setting; (4) PET/CT and SUVmax for prediction of prognosis; (5) miscellanea on the utility of PET in specific HNSCCs; (6) non-FDG PET tracers used in HNSCC. Promising results have been obtained so far. Despite the encouraging outcomes, more investigations are needed to warrant the value of this technique, especially in the pre-treatment setting.

Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 94:153–156PubMedCrossRef

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403PubMedCrossRef

Oyen WJ, Marres HA, Kaanders JH (2011) Progress in nuclear medicine procedures in head and neck oncology. Q J Nucl Med Mol Imaging. 55:485–486PubMed

Corvò R (2007) Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 85:156–170PubMedCrossRef

Ha PK, Hdeib A, Goldenberg D et al (2006) The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 132:12–16PubMedCrossRef

Miller FR, Hussey D, Beeram M et al (2005) Positron emission tomography in the management of unknown primary head and neck carcinoma. Arch Otolaryngol Head Neck Surg 131:626–629PubMedCrossRef

Gupta T, Master Z, Kannan S et al (2011) Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 38:2083–2095PubMedCrossRef

Scott AM, Gunawardana DH, Bartholomeusz D et al (2008) PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nucl Med 49:1593–1600PubMedCrossRef

Allen-Auerbach M, Weber WA (2009) Measuring response with FDGPET: methodological aspects. Oncologist 14:369–377. doi:10.1634/theoncologist.2008-0119 PubMedCrossRef

10.

Schöder H, Fury M, Lee N et al (2009) PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 50(Suppl 1):74S–88S. doi:10.2967/jnumed.108.057208 PubMedCrossRef

11.

Lin C, Itti E, Haioun C et al (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48:1626–1632PubMedCrossRef

12.

Sasaki R, Komaki R, Macapinlac H et al (2005) [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23:1136–1143PubMedCrossRef

13.

Lee SW, Nam SY, Im KC et al (2008) Prediction of prognosis using standardized uptake value of 2–18F- fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 87:211–216PubMedCrossRef

14.

Xie P, Yue JB, Fu Z et al (2010) Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol 21(5):1078–1082PubMedCrossRef

15.

Xie P, Yue JB, Zhao HX et al (2010) Prognostic value of 18F-FDG PET/CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol 136(6):883–889PubMedCrossRef

16.

Lee P, Weerasuriya DK, Lavori PW et al (2007) Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 69:328–333PubMedCrossRef

17.

Roh JL, Ryu CH, Choi SH et al (2007) Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. J Nucl Med 48(2):240–246PubMed

18.

Dobert N, Kovacs AF, Menzel C et al (2005) The prognostic value of FDG PET in head and neck cancer. Correlation with histopathology. Q J Nucl Med Mol Imaging 49(3):253–257PubMed

19.

Valk PE, Pounds TR, Tesar RD et al (1996) Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 23:737–743PubMedCrossRef

20.

Hollenbeak CS, Lowe VJ, Stack BC Jr (2001) The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck. Cancer 92:2341–2348PubMedCrossRef

21.

Johnson JT, Branstetter BF 4th (2014) PET/CT in head and neck oncology: state-of-the-art 2013. Laryngoscope. 124(4):913–915. doi:10.1002/lary.23942 Epub 2014 Feb 10 PubMedCrossRef

22.

Fogh SE, Kubicek GJ, Champ C et al (2012) Value of fluoro-2-deoxy-d-glucose- positron emission tomography for detecting metastatic lesions in head and neck cancer. Am J Clin Oncol 35(4):311–315. doi:10.1097/COC.0b013e3181ec5f2e PubMedCrossRef

23.

Stokkel MP, ten Broek FW, Hordijk GJ et al (2000) Preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emission tomography. Ann Surg 231(2):229–234PubMedPubMedCentralCrossRef

24.

Ng SH, Yen TC, Chang JT et al (2006) Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol 24(27):4371–4376PubMedCrossRef

25.

Roh JL, Yeo NK, Kim JS et al (2007) Utility of 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol 43(9):887–893PubMedCrossRef

26.

Murakami R, Uozumi H, Hirai T et al (2007) Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 68(2):377–382PubMedCrossRef

27.

Yamazaki Y, Saitoh M, Notani K et al (2008) Assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer. Ann Nucl Med 22(3):177–184PubMedCrossRef

28.

Rodrigues RS, Bozza FA, Christian PE et al (2009) Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck. J Nucl Med 50(8):1205–1213PubMedCrossRef

29.

Schwartz DL, Ford E, Rjendran J et al (2005) FDG-PET/CT imaging or pre-radiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 61:129–136PubMedCrossRef

30.

Nguyen A, Luginbuhl A, Cognetti D et al (2014) Effectiveness of PET/CT in the preoperative evaluation of neck disease. Laryngoscope 124(1):159–164PubMedCrossRef

31.

Kyzas PA, Evangelou E, Denaxa-Kyza D et al (2008) 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 100(10):712–720PubMedCrossRef

32.

Roh JL, Park JP, Kim JS et al (2014) 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study. Radiology 271(1):153–161PubMedCrossRef

33.

Ozer E, Naiboğlu B, Meacham R et al (2012) The value of PET/CT to assess clinically negative necks. Eur Arch Otorhinolaryngol 269(11):2411–2414PubMedCrossRef

34.

Schöder H, Carlson DL, Kraus DH et al (2006) 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 47:755–762PubMed

35.

Richard C, Prevot N, Timoshenko AP et al (2010) Preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography imaging in head and neck cancer: does it really improve initial N staging? Acta Otolaryngol 130:1421–1424PubMedCrossRef

36.

Lee SH, Huh SH, Jin SM et al (2012) Diagnostic value of only 18F-fluorodeoxyglucose positron emission tomography/computed tomography-positive lymph nodes in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 147(4):692–698 Epub 2012 Apr 24 PubMedCrossRef

37.

van den Brekel MW, van der Waal I, Meijer CJ et al (1996) The incidence of micrometastases in neck dissection specimens obtained from elective neck dissections. Laryngoscope 106(8):987–991PubMedCrossRef

38.

Fukui MB, Blodgett TM, Snyderman CH et al (2005) Combined PET/CT in the head and neck. Part 2. Diagnostic uses and pitfalls of oncologic imaging. RadioGraphics 25(4):913–930PubMedCrossRef

39.

Pentenero M, Cistaro A, Brusa M, Ferraris MM, Pezzuto C, Carnino R, Colombini E, Valentini MC, Giovanella L, Spriano G, Gandolfo S (2008) Accuracy of 18F-FDG-PET/CT for staging of oral squamous cell carcinoma. Head Neck. 30(11):1488–1496PubMedCrossRef

40.

van den Brekel MW, Stel HV, Castelijns JA et al (1990) Cervical lymph node metastasis: assessment of radiologic criteria. Radiology 177(2):379–384PubMedCrossRef

41.

Kastrinidis N, Kuhn FP, Hany TF et al (2013) 18F-FDG-PET/CT for the assessment of the contralateral neck in patients with head and neck squamous cell carcinoma. Laryngoscope 123(5):1210–1215. doi:10.1002/lary.23944 Epub 2013 Feb 20 PubMedCrossRef

42.

Carlson ER, Schaefferkoetter J, Townsend D et al (2013) The use of multiple time point dynamic positron emission tomography/computed tomography in patients with oral/head and neck cancer does not predictably identify metastatic cervical lymph nodes. J Oral Maxillofac Surg 71(1):162–177. doi:10.1016/j.joms.2012.03.028 Epub 2012 Jun 26 PubMedCrossRef

43.

Eiber M, Souvatzoglou M, Pickhard A et al (2012) Simulation of a MR-PET protocol for staging of head-and-neck cancer including Dixon MR for attenuation correction. Eur J Radiol 81(10):2658–2665. doi:10.1016/j.ejrad.2011.10.005 Epub 2011 Nov 10 PubMedCrossRef

44.

Ciernik IF, Dizendorf E, Baumert BG et al (2003) Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57:853PubMedCrossRef

45.

Daisne JF, Duprez T, Weynand B et al (2004) Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233:93–100PubMedCrossRef

46.

Schober O (2012) PET/CT in head squamous cell carcinoma with an unknown primary: significant diagnostic benefit in a prospective clinical trial. Strahlenther Onkol 188:637–638PubMedCrossRef

47.

Fleming AJ, Smith SP, Paul CM et al (2007) Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 117:1173–1179PubMedCrossRef

48.

Koshy M, Paulino AC, Howell R et al (2005) F-18 FDG PET/CT fusion in radiotherapy treatment plan-ning for head and neck cancer. Head Neck 27:494–502PubMedCrossRef

49.

Abramyuk A, Appold S, Zöphel K et al (2013) Modification of staging and treatment of head and neck cancer by FDG-PET/CT prior to radiotherapy. Strahlenther Onkol 189(3):197–201. doi:10.1007/s00066-012-0283-0 Epub 2013 Jan 19 PubMedCrossRef

50.

Kolarova I, Vanasek J, Kandrnal V et al (2012) PET/CT significance for planning radiotherapy of head and neck cancer. Neoplasma 59(5):536–540. doi:10.4149/neo_2012_069 PubMedCrossRef

51.

Wang K, Heron DE, Flickinger JC et al (2012) A retrospective, deformable registration analysis of the impact of PET/CT planning on patterns of failure instereotactic body radiation therapy for recurrent head and neck cancer. Head Neck Oncol 19(4):12. doi:10.1186/1758-3284-4-12 CrossRef

52.

Ritoe SC, Krabbe PF, Kaanders JH et al (2004) Value of routine follow-up for patients cured of laryngeal carcinoma. Cancer 101:1382–1389PubMedCrossRef

53.

Boysen M, Lovdal O, Tausjo J et al (1992) The value of follow-up in patients treated for squamous cell carcinoma of the head and neck. Eur J Cancer 28:426–430PubMedCrossRef

54.

NCCN Guidelines. Version 1.2011 (2011) Head and Neck Cancers. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site

55.

Rose PG, Adler LP, Rodriguez M et al (1999) Positron emission tomography for evaluating paraaortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 17:41–45PubMed

56.

Hain SF, O’Doherty MJ, Timothy AR et al (2000) Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 27:590–594PubMedCrossRef

57.

Ding M, Newman F, Raben D (2005) New radiation therapy techniques for the treatment of head and neck cancer. Otolaryngol Clin North Am 38:371–395PubMedCrossRef

58.

Yao M, Smith RB, Graham MM et al (2005) The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 63:991–999PubMedCrossRef

59.

Andrade RS, Heron DE, Degirmenci B et al (2006) Post-treatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 65:1315–1322PubMedCrossRef

60.

McDermott M, Hughes M, Rath T et al (2013) Negative predictive value of surveillance PET/CT in head and neck squamous cell cancer. AJNR Am J Neuroradiol 34(8):1632–1636. doi:10.3174/ajnr.A3494 Epub 2013 May 2 PubMedCrossRef

61.

Ul-Hassan F, Simo R, Guerrero-Urbano T et al (2013) Can (18)F-FDG PET/CT reliably assess response to primary treatment of head and neck cancer? Clin Nucl Med 38(4):263–265. doi:10.1097/RLU.0b013e31828165a8 PubMedCrossRef

62.

Beswick DM, Gooding WE, Johnson JT et al (2012) Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/computed tomography monitoring. Laryngoscope 122(7):1512–1517. doi:10.1002/lary.23341 PubMedPubMedCentralCrossRef

63.

Greven KM, Williams DW 3rd, McGuirt WF Sr et al (2001) Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23:942e6CrossRef

64.

Nakamura S, Toriihara A, Okochi K et al (2013) Optimal timing of post-treatment [18F]fluorodeoxyglucose-PET/CT for patients with head and neck malignancy. Nucl Med Commun 34(2):162–167. doi:10.1097/MNM.0b013e32835bdfe3 PubMedCrossRef

65.

Ceulemans G, Voordeckers M, Farrag A et al (2011) Can 18-FDG-PET during radiotherapy replace post-therapy scanning for detection/demonstration of tumor response in head-and-neck cancer? Int J Radiat Oncol Biol Phys 81:938PubMedCrossRef

66.

Uzel EK, Ekmekcioglu O, Elicin O et al (2013) Is FDG -PET/CT a valuable tool in prediction of persistent disease in head and neck cancer. Asian Pac J Cancer Prev 14(8):4847–4851PubMedCrossRef

67.

Prestwich RJ, Subesinghe M, Gilbert A et al (2012) Delayed response assessment with FDG-PET/CT following (chemo) radiotherapy for locally advanced head and neck squamous cell carcinoma. Clin Radiol 67(10):966–975. doi:10.1016/j.crad.2012.02.016 Epub 2012 May 15 PubMedCrossRef

68.

Fakhry N, Michel J, Colavolpe C et al (2012) Screening for distant metastases before salvage surgery in patients with recurrent head and neck squamous cell carcinoma: a retrospective case series comparing thoraco-abdominal CT, positron emission tomography and abdominal ultrasound. Clin Otolaryngol 37(3):197–206. doi:10.1111/j.1749-4486.2012.02481.x PubMedCrossRef

69.

Yi JS, Kim JS, Lee JH et al (2012) 18F-FDG PET/CT for detecting distant metastases in patients with recurrent head and neck squamous cell carcinoma. J Surg Oncol 106(6):708–712. doi:10.1002/jso.23185 Epub 2012 Jun 4 PubMedCrossRef

70.

Gourin CG, Watts T, Williams HT et al (2009) Identification of distant metastases with PET-CT in patients with suspected recurrent head and neck cancer. Laryngoscope 119(4):703–706. doi:10.1002/lary.20118 PubMedCrossRef

71.

Kostakoglu L, Fardanesh R, Posner M et al (2013) Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck. Oncologist 18(10):1108–1117. doi:10.1634/theoncologist.2013-0068 Epub 2013 Sep 13 PubMedPubMedCentralCrossRef

72.

Rangaswamy B, Fardanesh MR, Genden EM et al (2013) Improvement in the detection of locoregional recurrence in head and neck malignancies: F-18fluorodeoxyglucose-positron emission tomography/computed tomography compared to high-resolution contrast-enhanced computed tomography and endoscopic examination. Laryngoscope. 123(11):2664–2669. doi:10.1002/lary.24077 Epub 2013 Apr PubMedCrossRef

73.

Kim JW, Roh JL, Kim JS et al (2013) (18)F-FDG PET/CT surveillance at 3–6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma. Br J Cancer 109(12):2973–2979. doi:10.1038/bjc.2013.668 Epub 2013 Oct 22 PubMedPubMedCentralCrossRef

74.

Siddiqui F, Min Y (2014) Application of fluorodeoxyglucose positron emission tomography in the management of head and neck cancers. World J Radiol 6(6):238–251. doi:10.4329/wjr.v6.i6.238 PubMedPubMedCentralCrossRef

75.

Xie P, Minghuan L, Hanxi Z et al (2011) 18F-FDG PET or PET/CT to evaluate prognosis for head and neck cancer: a meta-analysis. J Cancer Res Clin Oncol 137(7):1085–1093. doi:10.1007/s00432-010-0972-y PubMedCrossRef

76.

Higgins KA, Jk Hoang et al (2012) Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer : tumor SUVmean has superior prognostic value. Int J Radiat Oncol Biol Phys 82(2):548–553. doi:10.1016/j.ijrobp.2010.11.050 Epub 2011 Jan 27 PubMedCrossRef

77.

Abgral R, Le Roux Py J, Rousset S et al (2013) Prognostic value of dual-time-point 18F-FDG PET/CT imaging in patients with head and neck squamous cell carcinoma. Nucl Med Commun 34(6):551–556. doi:10.1097/MNM.0b013e32836089ab PubMedCrossRef

78.

Abgral R, Keromnes N, Robin P et al (2014) Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma. Eur J Nuclear Med Mol Imaging 41(4):659–667. doi:10.1007/s00259-013-2618-1 CrossRef

79.

Abd El-hafez YG, Hm Moustafa et al (2013) Total lesion glycolysis : a possible new prognostic parameter in oral cavity squamous cell carcinoma. Oral Oncol 49(3):261–268. doi:10.1016/j.oraloncology.2012.09.005 Epub 2012 Oct 1 PubMedCrossRef

80.

Hm Imsande, Jm Davison, Mt Truong et al (2011) Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma. AJR Am J Roentgenol 197(4):976–980. doi:10.2214/AJR.10.4884 CrossRef

81.

Nakajo M, Kajiya Y, Tani A et al (2012) FDG PET/CT and diffusion-weighted imaging of head and neck squamous cell carcinoma : comparison of prognostic significance between primary tumor standardized uptake value and apparent diffusion coefficient. Clin Nucl Med 37(5):475–480. doi:10.1097/RLU.0b013e318248524a PubMedCrossRef

82.

Joo YH, Ier Yoo, Kj Cho et al (2013) Standardized uptake value and resection margin involvement predict outcomes in pN0 head and neck cancer. Otolaryngol Head Neck Surg. 149(5):721–726. doi:10.1177/0194599813500630 Epub 2013 Aug 6 PubMedCrossRef

83.

Joo YH, Ier Yoo, Kj Cho et al (2014) Prognostic value of preoperative 18F-FDG PET/CT for primary head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 271(6):1685–1691. doi:10.1007/s00405-013-2605-y Epub 2013 Aug 15 PubMedCrossRef

84.

Suzuki H, Kato K, Fujimoto Y et al (2014) Prognostic value of (18)F-fluorodeoxyglucose uptake before treatment for pharyngeal cancer. Ann Nuclear Med 28(4):356–362. doi:10.1007/s12149-014-0817-x CrossRef

85.

Suzuki H, Kato K, Fujimoto Y et al (2013) 18F-FDG-PET/CT predicts survival in hypopharyngeal squamous cell carcinoma. Ann Nucl Med 27(3):297–302. doi:10.1007/s12149-013-0686-8 Epub 2013 Jan 22 PubMedCrossRef

86.

Chan JY, Vl Chow, Vw Mok et al (2012) Prediction of surgical outcome using plasma epstein-barr virus DNA and (18) F-FDG PET/CT scan in recurrent nasopharyngeal carcinoma. Head Neck 34(4):541–545. doi:10.1002/hed.21768 Epub 2011 Apr 26 PubMedCrossRef

87.

Joo YH, Ier Yoo, Kj Cho et al (2013) Extracapsular spread and FDG PET/CT correlations in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 42(2):158–163. doi:10.1016/j.ijom.2012.11.006 Epub 2012 Dec 6 PubMedCrossRef

88.

Seol JH, Kim J, Lee JD et al (2013) The feasibility of 18F-fluorodeoxyglucose-positron emission tomography uptake as a prognostic factor for paranasal sinus malignancy. Am J Rhinol Allergy 27(2):118–122. doi:10.2500/ajra.2013.27.3848 PubMedCrossRef

89.

Ito K, Shimoji K, Miyata Y et al (2014) Prognostic value of post-treatment (18)F-FDG PET/CT for advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy. Chin J Cancer Res Chung-Kuo Yen Cheng Yen Chiu 26(1):30–37. doi:10.3978/j.issn.1000-9604.2014.01.06 PubMed

90.

Kikuchi M, Nakamoto Y, Shinohara S et al (2013) Early evaluation of neoadjuvant chemotherapy response using FDG-PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma. Int J Clin Oncol. 18(3):402–410. doi:10.1007/s10147-012-0393-9 Epub 2012 Mar 9 PubMedCrossRef

91.

Sherriff JM, Ogunremi B, Colley S et al (2012) The role of positron emission tomography/CT imaging in head and neck cancer patients after radical chemoradiotherapy. Br J Radiol 1019(85):e1120–e1126. doi:10.1259/bjr/20976707 CrossRef

92.

Querellou S, Abgral R, Le Roux PY et al (2012) Prognostic value of fluorine-18 fluorodeoxyglucose positron-emission tomography imaging in patients with head and neck squamous cell carcinoma. Head Neck 34(4):462–468. doi:10.1002/hed.21765 PubMedCrossRef

93.

Chung MK, Jeong HS, Park SG, Jang JY et al (2009) Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res 15(18):5861–5868PubMedCrossRef

94.

La TH, Filion EJ, Turnbull BB et al (2009) Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 74(5):1335–1341PubMedPubMedCentralCrossRef

95.

Cheng NM, Fang YH, Chang JT et al (2013) Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma. J Nucl Med 54(10):1703–1709PubMedCrossRef

96.

Picchio M, Kirienko M, Mapelli P, Dell’Oca I et al (2014) Predictive value of pre-therapy (18)F-FDG PET/CT for the outcome of (18)F-FDG PET-guided radiotherapy in patients with head and neck cancer. Eur J Nucl Med Mol Imaging 41(1):21–31PubMedCrossRef

97.

Seol YM, Kwon BR, Song MK et al (2010) Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol 49(2):201–208PubMedCrossRef

98.

Choi KH, Yoo Ie R, Han EJ et al (2011) Prognostic value of metabolic tumor volume measured by (18)F-FDG PET/CT in locally advanced head and neck squamous cell carcinomas treated by surgery. Nucl Med Mol Imaging 45(1):43–51PubMedCrossRef

99.

Romesser PB, Qureshi MM, Shah BA et al (2012) Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med 26(7):527–534PubMedPubMedCentralCrossRef

100.

Tang C, Murphy JD, Khong B et al (2012) Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys 83(5):1514–1520PubMedPubMedCentralCrossRef

101.

Chu KP, Murphy JD, La TH et al (2012) Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes. Int J Radiat Oncol Biol Phys 83(5):1521–1527PubMedPubMedCentralCrossRef

102.

Cheng NM, Chang JT, Huang CG et al (2012) Prognostic value of pretreatment (1)(8)F-FDG PET/CT and human papillomavirus type 16 testing in locally advanced oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging 39(11):1673–1684PubMedCrossRef

103.

Koyasu S, Nakamoto Y, Kikuchi M, Suzuk K et al (2014) Prognostic value of pretreatment 18F-FDG PET/CT parameters including visual evaluation in patients with head and neck squamous cell carcinoma. AJR Am J Roentgenol 202(4):851–858PubMedCrossRef

104.

Matsubara R, Kawano S, Chikui T et al (2012) Clinical significance of combined assessment of the maximum standardized uptake value of F-18 FDG PET with nodal size in the diagnosis of cervical lymph node metastasis of oral squamous cell carcinoma. Acad Radiol. 19:708–717PubMedCrossRef

105.

Mochizuki Y, Omura K, Nakamura S et al (2012) Preoperative predictive model of cervical lymph node metastasis combining fluorine-18 fluorodeoxyglucose positron-emission tomography/computerized tomography findings and clinical factors in patients with oral or oropharyngeal squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 113:274–282PubMedCrossRef

106.

Liao CT, Fan KH, Lin CY et al (2012) Impact of a second FDG PET scan before adjuvant therapy for the early detection of residual/relapsing tumours in high-risk patients with oral cavity cancer and pathological extracapsular spread. Eur J Nucl Med Mol Imaging 39:944–955PubMedCrossRef

107.

Chan JY, Sanguineti G, Richmon JD et al (2012) Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 138:1040–1046PubMedPubMedCentralCrossRef

108.

Ramakrishnan VR, Lee JY, O’Malley BW Jr et al (2013) 18-FDG-PET in the Initial Staging of Sinonasal Malignancy. Laryngoscope 123:2962–2966PubMedCrossRef

109.

Lee HJ, Kim JS, Roh JL et al (2013) Utility of quantitative 18 F-fluorodeoxyglucose uptake measurement to identify occult tonsillar carcinoma in patients with cervical metastasis of unknown primary tumours: a retrospective case-control study. Clin Otolaryngol 38:30–38PubMedCrossRef

110.

Hadiprodjo D, Ryan T, Truong MT et al (2012) Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters. AJR Am J Roentgenol 198:W185–W190PubMedCrossRef

111.

Kim MJ, Kim JS, Roh JL et al (2013) Utility of 18F-FDG PET/CT for detecting neck metastasis in patients with salivary gland carcinomas: preoperative planning for necessity and extent of neck dissection. Ann Surg Oncol 20:899–905PubMedCrossRef

112.

Kim JY, Lee SW, Kim JS et al (2012) Diagnostic value of neck node status using 18F-FDG PET for salivary duct carcinoma of the major salivary glands. J Nucl Med 53:881–886PubMedCrossRef

113.

Gilbert MR, Branstetter BF 4th, Kim S (2012) Utility of positron-emission tomography/computed tomography imaging in the management of the neck in recurrent laryngeal cancer. Laryngoscope 122:821–825PubMedCrossRef

114.

Fletcher JW, Djulbegovic B, Soares HP et al (2008) Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 49:480–508PubMedCrossRef

115.

Bussink J, Kaanders JH, van der Graaf WT et al (2011) PET/CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol. 8(23):3–242

116.

Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 23:1409–1415PubMedCrossRef

117.

Troost EG, Schinagl DA, Bussink J et al (2010) Innovations in radiotherapy planning of head and neck cancers: role of PET. J Nucl Med 51:66–76PubMedCrossRef

118.

Komar G, Oikonen V, Sipilä H et al (2012) Noninvasive parametric blood flow imaging of head and neck tumours using [15O]H2O and PET/CT. Nucl Med Commun 33(11):1169–1178PubMedCrossRef

119.

Koh WJ, Bergman KS, Rasey JS et al (1995) Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 33:391–398PubMedCrossRef

120.

Rajendran JG, Mankoff DA, O’Sullivan F et al (2004) Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245–2252PubMedCrossRef

121.

Okamoto S, Shiga T, Yasuda K et al (2013) High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med. 54(2):201–207PubMedCrossRef

122.

Henriques de Figueiredo B, Merlin T, de Clermont-Gallerande H et al (2013) Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas. Strahlenther Onkol 189(12):1015–1019PubMedCrossRef

123.

Kikuchi M, Yamane T, Shinohara S et al (2011) 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med 25(9):625–633PubMedCrossRef

124.

Zips D, Zöphel K, Abolmaali N et al (2012) Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 105(1):21–28PubMedCrossRef

125.

Mortensen LS, Johansen J, Kallehauge J et al (2012) FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol 105(1):14–20PubMedCrossRef

126.

Servagi-Vernat S, Differding S, Hanin FX et al (2014) A prospective clinical study of (18) F-FAZA PET/CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Eur J Nucl Med Mol Imaging 41(8):1544–1552PubMedCrossRef

127.

Chen L, Zhang Z, Kolb HC et al (2012) ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO. Nucl Med Commun 33(10):1096–1102PubMedCrossRef

128.

Komar G, Lehtiö K, Seppänen M, et al. (2014) Prognostic value of tumour blood flow, [(18)F]EF5 and [(18)F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy. Eur J Nucl Med Mol Imaging [Epub ahead of print]

129.

Koopmans KP, Jager PL, Kema IP et al (2008) 111Inoctreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med 49:1232–1237PubMedCrossRef

130.

Van der Harst E, De Herder WW, Bruining HA et al (2001) 123[I] Metaiodobenzylguanidine and 111[In] octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86:685–693PubMed

131.

Naswa N, Sharma P, Nazar AH et al (2012) Prospective evaluation of 68 Ga-DOTA-NOC PET/CT in pheochromocytoma and paraganglioma: preliminary results from a single centre study. Eur Radiol 22:710–719PubMedCrossRef

132.

Maurice JB, Troke R, Win Z et al (2012) A comparison of the performance of ⁶⁸Ga-DOTATATE PET/CT and ¹²³I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 39(8):1266–1270PubMedCrossRef

133.

Schartinger VH, Dudás J, Decristoforo C et al (2013) ⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 40(9):1365–1372PubMedCrossRef

134.

Sharma P, Thakar A, Suman KCS et al (2013) 68 Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma. J Nucl Med 54(6):841–847PubMedCrossRef

135.

Shields AF, Grierson JR, Kozawa SM et al (1996) Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol 23:17–22PubMedCrossRef

136.

Shields AF, Grierson JR, Dohmen BM et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334–1336PubMedCrossRef

137.

Rasey JS, Grierson JR, Wiens LW et al (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A 549 carcinoma cells. J Nucl Med 43:1210–1217PubMed

138.

Troost EG, Bussink J, Hoffmann AL et al (2010) 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 51(6):866–874PubMedCrossRef

139.

Hoeben BA, Troost EG, Span PN et al (2013) 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med 54(4):532–540PubMedCrossRef

140.

Hoshikawa H, Kishino T, Mori T, Nishiyama Y et al (2012) Comparison of (18)F-FLT PET and (18)F-FDG PET for detection of cervical lymph node metastases in head and neck cancers. Acta Otolaryngol 132(12):1347–1354PubMedCrossRef

141.

Stern PH, Hoffman RM (1984) Elevated overall rates of transmethylation in cell lines from diverse human tumors. Vitro 20(8):663–670CrossRef

142.

Stern PH, Wallace CD, Hoffman RM (1984) Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol 119(1):29–34PubMedCrossRef

143.

Toubaru S, Yoshikawa K, Ohashi S, Tanimoto K, Hasegawa A, Kawaguchi K, Saga T, Kamada T (2013) Accuracy of methionine-PET in predicting the efficacy of heavy-particle therapy on primary adenoid cystic carcinomas of the head and neck. Radiat Oncol 13(8):143CrossRef

Titel: The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature
verfasst von: Giovanni Cammaroto
Natale Quartuccio
Alessandro Sindoni
Francesca Di Mauro
Federico Caobelli
Young AIMN Working Group
Publikationsdatum: 14.05.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Oto-Rhino-Laryngology / Ausgabe 8/2016
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-015-3651-4

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature

Abstract

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

Influence of allelic variations of hypoxia-related and DNA repair genes on patient outcome and toxicity in head and neck cancer treated with radiotherapy plus cetuximab

Malignant otitis externa in a healthy non-diabetic patient

Nomenclature proposal to describe vocal fold motion impairment

The effect of the transducers on paediatric thresholds estimated with auditory steady-state responses

Radiotherapy alone or combined with chemotherapy as definitive treatment for squamous cell carcinoma of the tonsil

Training model for endoscopic sinus surgery using lamb’s head

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO